ArticleFrontiers in cellular and infection microbiology2017
Efflux Pump Overexpression Contributes to Tigecycline Heteroresistance in
Article in Frontiers in cellular and infection microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 71 citations in OpenAlex.
- Beyond susceptibility results: understanding the clinical and diagnostic burden of bacterial heteroresistance.Molecular biology reports · 2026Review
- Chitosan-dextran sulfate nanocapsules for enhanced tigecycline efficacy against non-typhoidal Salmonella enterica.Scientific reports · 2026Article
- Transient AdeABC-mediated eravacycline resistance in carbapenem-resistant Acinetobacter baumannii ST2: a mutation-independent efflux pump adaptation.Annals of clinical microbiology and antimicrobials · 2026Article
- Salmonellosis as a One Health-One Biofilm Challenge: Biofilm Formation byPharmaceuticals (Basel, Switzerland) · 2025Review
- Plasmid pHXY0908 confers ciprofloxacin heteroresistance to Salmonella enterica serovar typhimurium ATCC 14028 by regulating efflux pump gene expression.BMC microbiology · 2025Article
- Article
- The investigation of molecular epidemiological characteristics and resistance mechanism of tigecycline resistantFrontiers in cellular and infection microbiology · 2025Article
- Analysis of Efflux Pump Contributions and Plasmid-Mediated Genetic Determinants in Ciprofloxacin-ResistantPathogens (Basel, Switzerland) · 2024Article
- Emergence of plasmid-borneMicrobiology spectrum · 2024Article
- Emergence of heteroresistance to carbapenems in Gram-negative clinical isolates from two Egyptian hospitals.BMC microbiology · 2024Article
- AcrAB-TolC efflux pump overexpression and tet(A) gene mutation increase tigecycline resistance in Klebsiella pneumoniae.World journal of microbiology & biotechnology · 2024Article
- Co-transfer of IncFII/IncFIB and IncFII plasmids mediated by IS26 facilitates the transmission of mcr-8.1 and tmexCD1-toprJ1.Annals of clinical microbiology and antimicrobials · 2024Article
- The tigecycline resistance mechanisms in Gram-negative bacilli.Frontiers in cellular and infection microbiology · 2024Review
- Molecular mechanisms of tigecycline-resistance amongFrontiers in cellular and infection microbiology · 2024Review
- A promising metabolite, 9-aminominocycline, restores the sensitivity of tigecycline againstFrontiers in microbiology · 2024Article
- Bacterial memory in antibiotic resistance evolution and nanotechnology in evolutionary biology.iScience · 2023Review
- Antimicrobial Resistance ofPathogens (Basel, Switzerland) · 2022Article
- In vitro activity and adaptation strategies of eravacycline in clinical Enterococcus faecium isolates from China.The Journal of antibiotics · 2022Article
- Antidiarrheal and Antibacterial Activities of Monterey Cypress Phytochemicals: In Vivo and In Vitro Approach.Molecules (Basel, Switzerland) · 2022Article
- Relationships between Efflux Pumps and Emergence of Heteroresistance: A Comprehensive Study on the Current Findings.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial heteroresistance has been identified in several combinations of bacteria and antibiotics, and it complicated the therapeutic strategies. Tigecycline is being used as one of the optimal options for the treatment of infections caused by multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.